Figure S1. The details of therapeutic regimens according to AML-BFM-2012 Registry and AML-BFM-2019 protocols

AML-BFM 2012 Registry



AML-BFM 2019



Induction phases:
AIE: cytarabine 100 mg/m2/day continuous infusion on days 1 and 2, followed by 30 min infusion every 12 h on days 3–8; idarubicin 12 mg/m2/day, 30 min infusion days 3, 4, and 5; etoposide 150 mg/m2/day, 60 min infusion on days 6–8.
HAM: cytarabine 3 g/m2/dose, 3 h infusion every 12 h on days 1–3 (6 doses); mitoxantrone 10 mg/m2/day, 30 min infusion on days 3 and 4.

Consolidation phases:
AI/2-CDA: cytarabine 500 mg/m2/day, 96-h infusion on days 1–4; idarubicin 12 mg/m2/day, 30 min infusion on days 3 and 5; 2-chloro-2-deoxyadenosine 6 mg/m2/day, 30 min infusion, on days 1 and 3.
AI: cytarabine 500 mg/m2/day, 96-hours infusion on days 1–4; idarubicin 12 mg/m2/day, 30 min infusion on days 3 and 5.
hAM: cytarabine 1 g/m2/dose, 3 h infusion every 12 h on days 1–3 (6 doses); mitoxantrone 10 mg/m2/day, 30 min infusion on days 3 and 4.
HAE: cytarabine 3 g/m2/dose, 3 h infusion every 12 h on days 1–3 (6 doses); etoposide 125 mg/m2/day, 60 min infusion on days 2–5.

Maintenance:
AML-BFM 2012: daily thioguanine 40 mg/m2/day, orally; cytarabine 40 mg/m2/day, i.v. or s.c., 4 days every 4 weeks for 1 year.

Table S1. Stratification to risk group according to treatment protocols.

Protocol	AML-BFM 2012 Registry	AML-BFM 2019
Standard risk group (SRG)	t(8;21), inv(16), t(1;11), NPM1, CEBPdm[a]	Inv(16)(p13.1q22) t(16;16)(p13;q22) t(8;21)(q22;q22) t(1;11) (q21;q23) Normal karyotype and NPM1-mutation Normal karyotype and CEBPA (double mutation)[a]
Intermediate risk group (IRG)	All others [b]	All others[b]
High risk group (HRG)	t(4;11), t(5;11), t(6;11), t(10;11), t(6;9), t(7;12), der12p, isolated monosomy 7, t(9;22), FLT3-ITD and WT1mut, complex karyotype	12p/ t(2;12), 5/5q, FLT-ITD and WT1mut, 7 (not in combination with favorable/MLL-aberrations), t(4;11)(q21;q23); KMT2A::AF4, t(5;11)(q35.3;p15);NUP98::NSD1, t(6;11)(q27;q23);KMT2A::AF6, t(10;11)(p12;q23);KMT2A::AF10, t(6;9)(p23;q34), t(7;12)(q36;p13), t(9;22)(q34;q11), complex karyotype, inv(3)(q21q26.2)/t(3;3)(q21;q26.2), t(16;21)(p11;q22);FUS::ERG, Inv(16)(p13.3q24.3);CBFA2T3::GLIS2

[a] In case of bone marrow blasts >20% on the days 21-28—reclassification to IRG
[b] In case of bone marrow blasts > 20% on the days 21-28 or >5% on the days 42-56—reclassification to HRG